Only logged in customers who have purchased this product may leave a review.
Cartalax 20mg
Research Grade Peptide
- Research Grade
- 99% Purity
- Third-Party Verified
Reference Strength: 20mg
R799,00
CAS: Not established (no universally verified public CAS number)
Formula: C12H19N3O8
Molecular Weight: 333.29 g/mol
Chemical Name / Amino Acid Sequence: Ala-Glu-Asp (AED)
Availability: In stock
SKU: LAX20
Cartalax 20mg
R799,00
Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp; AED) investigated for its potential role in connective tissue biology, extracellular matrix homeostasis and healthy ageing.
Availability: In stock
Included with your purchase
Each qualifying product includes 3ml of 0.9% Benzyl Alcohol Bacteriostatic Water.
Complimentary Purchase Kit
Every qualifying vial includes a complimentary purchase kit at no additional cost.
Research Overview
About Cartalax 20mg
Cartalax belongs to the Khavinson peptide bioregulator family. Laboratory studies have investigated its effects on fibroblast activity, cartilage biology, gene expression and cellular maintenance. Published human dosing data remain limited.
How It Works in Research
Preclinical studies suggest Cartalax (AED) may modulate gene expression involved in connective tissue maintenance. Laboratory models have reported increased Ki-67, SIRT-1 and SIRT-6 expression, reduced p53 and caspase-3 activity, and decreased MMP-9 synthesis, supporting extracellular matrix homeostasis.
Research Applications
• Connective tissue • Cartilage biology • Fibroblast function • Healthy ageing • Extracellular matrix • Cellular repair
Researchers study Cartalax because it may help regulate cellular processes involved in maintaining healthy connective tissue and cartilage.
Product Specifications
- Product Name: Cartalax
- Alternate Chemical Name: AED (Alanyl-Glutamyl-Aspartic Acid)
- Other Names: AED peptide, T-31
- CAS Number: Not established (no universally verified public CAS number)
- PubChem CID: 87815447
- Molecular Formula: C12H19N3O8
- Molecular Weight: 333.29 g/mol
Research Information
- Amino Acid Sequence: Ala-Glu-Asp (AED)
- Reference Strength: 20 mg
- Appearance: White to off-white lyophilised powder
- Purity Standard: ≥98% (HPLC)
- Category: Khavinson Tripeptide Bioregulator
- Storage: 2–8°C after reconstitution
Mechanism of Action
Preclinical studies suggest Cartalax (AED) may modulate gene expression involved in connective tissue maintenance. Laboratory models have reported increased Ki-67, SIRT-1 and SIRT-6 expression, reduced p53 and caspase-3 activity, and decreased MMP-9 synthesis, supporting extracellular matrix homeostasis.
Potential Benefits in Research
Preclinical research has explored potential support for fibroblast proliferation, connective tissue maintenance, cartilage biology and healthy ageing.
Safety Profile
Preclinical research has explored potential support for fibroblast proliferation, connective tissue maintenance, cartilage biology and healthy ageing.
Research Applications
Connective tissue
Cartilage biology
Fibroblast function
Healthy ageing
Extracellular matrix
Cellular repair
Educational protocol only; published human clinical dosing remains limited.
REFERENCE RECONSTITUTION INFORMATION
Goal: Support connective tissue homeostasis and fibroblast function based on preclinical research. Schedule: Once-daily subcutaneous injections. Cycle Length: 8–12 weeks (optional extension to 16 weeks). Dose Range: 2–5 mg daily. Reconstitution: Add 3.0 mL bacteriostatic water to one 20 mg vial (6.67 mg/mL).
Always follow sterile preparation techniques when handling research peptides.
Educational protocol only; published human clinical dosing remains limited.
General Preparation
• Use a new sterile insulin syringe for each injection. • Rotate injection sites. • Inject at a consistent time each day. • Store refrigerated after reconstitution. • Educational protocol only; published human clinical dosing remains limited.
- Slowly add 3.0 mL bacteriostatic water down the inside wall of the vial. Allow the powder to dissolve naturally and gently swirl until clear. Do not shake vigorously.
CARTALAX (20MG)- RECONSTITUTION TABLES
Reference Handling Information
Reference information for laboratory handling of Cartalax 20mg.
- Schedule: Once-daily subcutaneous injections.
- Cycle Length: 8–12 weeks (optional extension to 16 weeks).
- Dose Range: 2–5 mg daily.
Reference Parameters (Dosing Protocol)
| Week / Phase | Daily Dose | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1–2 | 2 mg (2,000 mcg) | 30 units | 0.30 mL |
| Weeks 3–4 | 3 mg (3,000 mcg) | 45 units | 0.45 mL |
| Weeks 5–8 | 4 mg (4,000 mcg) | 60 units | 0.60 mL |
| Weeks 9–12 | 5 mg (5,000 mcg) | 75 units | 0.75 mL |
For laboratory research only.
Experimental Study Period
STUDY PERIOD
8–12 weeks (optional extension to 16 weeks).
RESEARCH CONTEXT
Support connective tissue homeostasis and fibroblast function based on preclinical research.
Once-daily subcutaneous injections.
View Certificate of Analysis
View Certificate of Analysis Each batch of Cartalax is independently tested by third-party laboratories. Download the Certificate of Analysis to verify purity, identity, and quality.
99.6%
Verified Purity
3rd Party
Lab Tested
Certified
Quality Assured
Related products
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
PURE PERFORMANCE LABS
Recommended Research Products
Explore related compounds commonly viewed alongside this product.
FOR RESEARCH PURPOSES ONLY
This product is intended for research and laboratory use only. Always consult qualified researchers and follow appropriate safety protocols.
Reviews
There are no reviews yet.